Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239455 | 0.94 | TDP1 (0.46) | L3MBTL1TDP1KCNH2TLR8TRPV1 | |
| SCHEMBL4584095 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL4585040 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL15344545 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL4586892 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL4585106 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL9013118 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL4585397 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL4584429 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 | |
| SCHEMBL4586718 | 0.92 | TDP1 (0.44) | L3MBTL1TDP1KCNH2TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206886-B | Gold (III) compound, method for preparing the same, and organic light emitting device using the same | 广东聚华印刷显示技术有限公司 | 2024-02-27 | — | — | CN | claimed |
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2023-03-30 | — | — | US | claimed |
| EP-3992357-A1 | COMPOSITION FOR SURFACE TREATMENT OF FIBERS AND FIBER TREATMENT METHOD | Beijing University of Chemical Technology (CN) | 2022-05-04 | — | — | EP | claimed |
| CN-114206886-A | Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same | 广东聚华印刷显示技术有限公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2021113492-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2021-06-10 | — | — | WO | claimed |
| WO-2021016814-A1 | LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2021-02-04 | — | — | WO | claimed |
| EP-1294699-B1 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORP (US) | 2016-04-13 | — | — | EP | claimed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | claimed |
| US-8334391-B2 | Functionalized heteroacenes | XEROX CORPORATION (US) | 2012-12-18 | — | — | US | claimed |
| CN-100494182-C | Regulatory factor of tumor necrosis alpha factor | GENZYME CORP (US) | 2009-06-03 | — | — | CN | claimed |
| US-7372071-B2 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20070260069-A1 | Functionalized heteroacenes | XEROX CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070235721-A1 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION | 2007-10-11 | — | — | US | claimed |
| US-6969728-B2 | Antiinflammatory agents | GENZYME CORPORATION (US) | 2005-11-29 | — | — | US | claimed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | claimed |
| CN-1441787-A | Modulators of TNF-alpha signaling | GENZYME CORP (US) | 2003-09-10 | — | — | CN | claimed |
| EP-1294699-A2 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | claimed |
| WO-2001087849-A2 | MODULATORS OF TNF- ALPHA SIGNALING | GENZYME CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| US-4900749-A | Isoprenoidamine compounds useful as antiulcer agents | SHIONOGI & CO., LTD. (JP) | 1990-02-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260069-A1 | Functionalized heteroacenes | SOD1, AHR, NR0B2 | L3MBTL1 1684/4885TDP1 3945/4885KCNH2 1459/4885 |
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | PLK1, DCK, CSNK1A1 | L3MBTL1 4831/4885TDP1 2280/4885KCNH2 2793/4885 |
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | L3MBTL1 4750/4885TDP1 3193/4885KCNH2 4618/4885 |
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | L3MBTL1 1295/4885TDP1 915/4885KCNH2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.